Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease

Journal of Neuroinflammation

Antonio Pisani¹  Diego Franciotta²  Paolo Stanzione⁴  Silvia Natoli³  Mariangela Pierantozzi⁴  Alessandro Stefani⁴  Valerio Pisani⁴ 

[1] Laboratory of Neurophysiology, Santa Lucia Foundation, IRCCS, Rome, Italy;Laboratory of Neuroimmunology, IRCCS, National Neurological Institute C. Mondino, Pavia, Italy;Intensive Care Unit, University of Rome ‘Tor Vergata’, Rome, Italy;Department of Neuroscience, University of Rome ‘Tor Vergata’, Rome, Italy

关键词: Parkinson’s disease;    Cerebrospinal fluid;    Blood-cerebrospinal fluid barrier;    Blood–brain barrier;    Albumin ratio;   

Others  :  1160329
DOI  :  10.1186/1742-2094-9-188

 received in 2012-05-08, accepted in 2012-07-16,  发布年份 2012

【 摘 要 】

Background

Alterations in blood–brain barrier permeability have been proposed to represent a relevant factor contributing to Parkinson’s disease progression. However, few studies have addressed this issue in patients at different stages of disease.

Methods

Albumin was measured in cerebrospinal fluid and serum samples obtained from 73 non-demented subjects with idiopathic Parkinson’s disease and 47 age-matched control subjects. The albumin ratio (AR) was calculated to assess blood-cerebrospinal fluid and blood–brain barrier function. The group of patients with Parkinson’s disease included 46 subjects with Hoehn-Yahr staging between 1 and 2 and 27, with a score ranging from 2.5 to 4.

Results

Statistically significant differences in albumin ratio were found between patients with advanced disease, and both early-stage and unaffected groups. Conversely, early-phase patients did not differ from healthy subjects. Additionally, dopaminergic treatment seems to exert a possible effect on AR values.

Conclusions

Our study demonstrates that possible dysfunction of the blood-cerebrospinal fluid barrier, blood–brain barrier, or both, characterize Parkinson’s disease progression. The associations between clinical scores, treatments and biochemical findings suggest a progressive impairment of barrier integrity during the course of the disease.

【 授权许可】

   
2012 Pisani et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

【 参考文献 】

• [1]Weiss N, Miller F, Cazaubon S, Couraud PO: The blood–brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009, 1788:842-857.
• [2]Hirsch EC, Hunot S: Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 2009, 8:382-397.
• [3]Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH: Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005, 57:176-179.
• [4]Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD: 6-Hydroxydopamine-induced alterations in blood–brain barrier permeability. Eur J Neurosci 2005, 22:1158-1168.
• [5]Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA: Endothelial proliferation and increased blood–brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006, 26:9448-9461.
• [6]Thompson EJ: Cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1995, 59:349-357.
• [7]Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F: A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
• [8]Reiber H: Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001, 310:173-186.
• [9]Gibb WR, Lees AJ: The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 1989, 15:27-44.
• [10]Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA: The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011, 82:1112-1118.
• [11]Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ: Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008, 5:55-59.
• [12]McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988, 38:1285-1291.
• [13]L’Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C, D’Adamo P, Zardini E, Andreoni L, Ihekwaba AE, Serra PA, Franciotta D, Martino G, Pluchino S, Marchetti B: Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Neurobiol Dis 2011, 41:508-527.
• [14]Droździk M, Białecka M, Myśliwiec K, Honczarenko K, Stankiewicz J, Sych Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics 2003, 13:259-263.
• [15]Hawkins RA, Mokashi A, Simpson IA: An active transport system in the blood–brain barrier may reduce levodopa availability. Exp Neurol 2005, 195:267-271.
• [16]Haussermann P, Kuhn W, Przuntek H, Muller T: Integrity of the blood-cerebrospinal fluid barrier in early Parkinson’s disease. Neurosci Lett 2001, 300:182-184.
• [17]Fisone G, Snyder GL, Aperia A, Greengard P: Na+, K(+)-ATPase phosphorylation in the choroid plexus: synergistic regulation by serotonin/protein kinase C and isoproterenol/cAMP-PK/PP-1 pathways. Mol Med 1998, 4:258-265.
• [18]Silverberg GD, Huhn S, Jaffe RA, Chang SD, Saul T, Heit G, Von Essen A, Rubenstein E: Downregulation of cerebrospinal fluid production in patients with chronic hydrocephalus. J Neurosurg 2002, 97:1271-1275.
• [19]Woitalla D, Goetze O, Kim JI, Nikodem AB, Schmidt WE, Przuntek H, Muller T: Levodopa availability improves with progression of Parkinson’s disease. J Neurol 2006, 253:1221-1226.